Prophylactic Sphincterotomy in Acute Biliary Pancreatitis Patients Unfit for Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

92 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-01

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of prophylactic endoscopic sphincterotomy (ES) in frail patients unfit for cholecystectomy following an episode of acute biliary pancreatitis (ABP).

Eligible patients will be randomized in a 1:1 ratio to either prophylactic ES during the index admission or conservative treatment. The primary endpoint is a composite of recurrent pancreatobiliary events within 12 months, including recurrent ABP, cholangitis, choledocholithiasis requiring endoscopic retrograde cholangiopancreatography (ERCP), or cholangiogenic liver abscess. Secondary outcomes include mortality, pancreatobiliary events requiring intensive care unit admission, post-ERCP complications, cholecystitis, and length of hospitalization.

A total of 92 patients will be enrolled. The trial will be led by the Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary, and conducted in accordance with Good Clinical Practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary Pancreatitis

NCT00987428

Pancreatitis Acute Biliary

TERMINATED NA

Comparing the Effects of EST and EPBD in Patients With Acute Biliary Pancreatitis

NCT02668081

Acute Biliary Pancreatitis

UNKNOWN NA

Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis

NCT06260878

Post-ERCP Acute Pancreatitis

RECRUITING PHASE4

Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction

NCT00688662

Sphincter of Oddi Dysfunction

COMPLETED NA

Enhanced Recovery in Acute Pancreatitis

NCT02813876

Acute Pancreatitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Biliary Pancreatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Prophylactic endoscopic sphincterotomy

Papillary cannulation and sphincterotomy techniques will be performed in adherence to the recommendations outlined in the ESGE (European Society of Gastrointestinal Endoscopy) guideline. All recommended measures for post-ERCP (Endoscopic Retrograde Cholangiopancreatography) pancreatitis prevention must be implemented, including the use of prophylactic pancreatic stents, rectal nonsteroidal anti-inflammatory drugs, and optimal hydration protocols where appropriate.

All rescue techniques may be utilized if necessary, in accordance with clinical judgment and guideline recommendations.

ERCP/ES (endoscopic sphincterotomy) will be performed by an experienced endoscopist, defined as someone who has performed more than 300 ERCPs in their lifetime and maintains a native papilla cannulation success rate of at least 90%.

If the ES cannot be performed during the initial ERCP, the number of further attempts is under the discretion of the endoscopist.

Group Type ACTIVE_COMPARATOR

Prophylactic endoscopic sphincterotomy

Intervention Type PROCEDURE

Participants in this arm will undergo prophylactic endoscopic sphincterotomy performed by experienced endoscopists, with all recommended preventive measures against post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) applied according to international guidelines.

Conservative treatment

This study arm will follow a conservative treatment strategy, and no endoscopic procedures will be performed.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prophylactic endoscopic sphincterotomy

Participants in this arm will undergo prophylactic endoscopic sphincterotomy performed by experienced endoscopists, with all recommended preventive measures against post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) applied according to international guidelines.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. adult patients (above 18 years)
2. naïve papilla
3. evidence of AP based on the Atlanta criteria:

* pain in the upper abdomen
* serum amylase or lipase concentration \> 3 times the upper limit of normal
* imaging features of acute pancreatitis on abdominal imaging
4. high probability of a biliary etiology:

* gallstones or biliary sludge on imaging (any type)
* dilated common bile duct on imaging defined as \> 8 mm in patients ≤ 75 years or \> 10 mm in patients \> 75 years
* abnormal liver enzymes (alanine aminotransferase \[ALT\] two times the upper limit of normal)
5. patients unfit for surgery due to the attending physician's decision e.g. American Society of Anesthesiologists (ASA) class ≥ III; severe heart failure with reduced ejection fraction \<40%, severe uncontrolled hypertension, chronic kidney disease stage four or five

Exclusion Criteria

1. previous cholecystectomy
2. previous endoscopic sphincterotomy or pancreatobiliary stenting
3. ERCP/ES is recommended by the guidelines (3)

* sign of cholangitis
* presence of CBD stone on any imaging
* signs of stone in endoscopic ultrasonography or magnetic resonance imaging in case of abnormal liver enzymes (persistently elevated ALT and aspartate aminotransferase (AST) with less than a 20% decrease over four days) or dilated CBD (defined as above)
4. chronic pancreatitis
5. estimated life expectancy \< 12 months
6. ERCP is contraindicated, e.g. the procedure cannot be carried out safely due to the patient's comorbidities or physical status; high risk of bleeding or contraindication of the discontinuation of the anticoagulation therapy.
7. ERCP is technically not feasible due to altered anatomy, e.g., total gastrectomy, Roux-en-Y gastric bypass anatomy
8. pancreatobiliary malignancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No